Abstract
Bioequivalence trials are carried out to compare two or more formulations of a drug containing the same active ingredient, in order to determine whether the different formulation give rise to comparable blood levels. We consider the 2 x 2 changeover experiment the compares two formulations, one of which is considered the standard. For a single univariate characteristic of the plasma concentration--time curve, a criterion for bioequivalence is proposed based on the posterior probability that the difference in formulation means is less than a specific percentage of the mean of the standard. The sensitivity of this posterior probability to alternative priors is investigated. Differences in carry-over effects can be incorporated within the Bayesian framework without restoring to the "all-or-nothing" approach implied by a preliminary test. The use of sequential experimentation is discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.